Navigation Links
ANA773 in Medical News

Anadys Pharmaceuticals to Present at the Citi Biotech Day

...interferons that acts via the TLR7 pathway. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in... of future results, and Anadys cannot provide any assurances that ANA598 or ana773 will not have unforeseen safety issues, will have favorable results in ongo...

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights

... of the first quarter of 2009. ana773 ana773 is an oral prodrug of a small molecule inducer of ...t led to no adverse findings. Anadys is exploring ana773 in two early clinical studies, one in HCV patients...

Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results

...r and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statement...of future results, and Anadys cannot provide any assurances that ANA598 and ana773 will not have unforeseen safety issues, will have favorable results in futu...

Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference

...nd an update on its clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. Additionally, Dr. Worland will par...7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor...

Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study

...tentially complementary agents: ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward...

Anadys Pharmaceuticals to Present at Bio Investor Forum

...or and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this p...of future results, and Anadys cannot provide any assurances that ANA598 and ana773 will not have unforeseen safety issues, will have favorable results in futu...
ANA773 in Medical Technology

Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells

Poster Presentation on April 17, 2007 at AACR SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion,...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in nature constit...

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

...entially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in nature cons...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

...or and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this p...of future results, and Anadys cannot provide any assurances that ANA598 and ana773 will not have unforeseen safety issues, will have favorable results in futu...

Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference

...Anadys and its three clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. The presentation will be simultaneous...R7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Stateme...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

...tentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward...

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

...anded HCV Development Presence Includes ANA598 and ana773 Acting via Independent but Potentially Co...l patients in a separate Phase I clinical trial of ana773 in oncology that is ongoing under an IND in the Un...ction of interferon-alpha dependent responses when ana773 is dosed every other day over 13 weeks, have convi...

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

...encement of dosing in a Phase I clinical trial for ana773 in cancer patients in February and this study of A...ve important clinical milestones in the ANA598 and ana773 programs; and (v) expectations regarding the evolu...adys cannot provide any assurances that ANA598 and ana773 will not have unforeseen safety issues, will have ...
ANA773 in Biological News

Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference

...ew of Anadys and its clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. The presentation will be simultane...7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor...
ANA773 in Biological Technology

Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that it has initiated dosing ANA773 in patients chronically infected with hepatitis C virus (HCV) in Part B of a two-part protocol designed to test ANA773 in both healthy volunteers and H...

Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients

SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that patient dosing has commenced in a Phase I study of ANA773, the company's oral TLR7 agonist prodrug, in patients with advanced solid tumors. This first-in-human trial is a safety and ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...imarily attributable to a $1.3 million decrease in ana773 development costs partially offset by $0.5 million...e strategic restructuring initiated in June 2009. ana773 development costs during the second quarter of 200...f hepatitis C. During the second quarter of 2008, ana773 development costs were primarily driven by the now...

Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results

...the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ana773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk fa...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

... Company intends to suspend further development of ana773 and is reducing its workforce by approximately 40%...titis C and oncology, Anadys intends to manage the ana773 programs as potential out-licensing opportunities.... plans, its focus of operations, management of its ana773 programs, its plans regarding the planned ANA598 P...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

...ter of 2008, partially offset by a decrease in our ana773 development costs. The ANA598 development costs w...s which were initiated during September 2008. Our ana773 development costs during the three months ended Ma...ha, telaprevir and PSI-6130. ana773 ...

Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results

...interferons that acts via the TLR7 pathway. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Stat... of future results, and Anadys cannot provide any assurances that ANA598 or ana773 will not have unforeseen safety issues, will have favorable results in ongo...

Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry

...ew of Anadys and its clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. The corporate presentation will be... the TLR7 pathway. The Company is also developing ana773 for the treatment of cancer. Safe Harbor...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

...entially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in natu...

Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

...nadys and its three clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. The presentation will be simul...7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Har...
Other Tags
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... OncLive proudly announces the 2015 Giants of ... a panel of eminent oncologists for landmark achievements that ... be introduced and celebrated TONIGHT at the 3rd Annual ... CDT at The Chicago Illuminating Company, 2110 S. Wabash ... groundbreaking accomplishments, in fields including translational research, gene therapy, ...
(Date:5/29/2015)... 2015 The report “Muscle Spasm ... on the therapeutic development for Muscle Spasm. Spasms ... the body, leading to many different symptoms and ... new targets and MOAs to produce first-in-class and ... review of Axillary Hyperhidrosis with 19 market data ...
(Date:5/29/2015)... AL (PRWEB) May 29, 2015 ... Fibromyalgia and Chronic Fatigue Syndrome is now offering ... Callers can learn about natural ways to reduce ... low moods, poor sleep, and brain fog. ... weekly Treating and Beating Fibromyalgia call in teleconferences ...
Breaking Medicine News(10 mins):Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
Other Contents